What is ImmunityBio, Inc.'s free cash flow?

ImmunityBio, Inc. (IBRX) reported free cash flow of -$77.14M in Q1 2026.

How has ImmunityBio, Inc.'s free cash flow changed year-over-year?

ImmunityBio, Inc.'s free cash flow increased by 11.4% year-over-year, from -$87.03M to -$77.14M.

What is the long-term trend for ImmunityBio, Inc.'s free cash flow?

Over 4 years (2021 to 2025), ImmunityBio, Inc.'s free cash flow has grown at a 0.1% compound annual growth rate (CAGR), from -$307.98M to -$308.78M.

ImmunityBio, Inc. IBRX Free cash flow

Free cash flow at other companies

Bristol-Myers SquibbBMY

$757M-55.3%

Johnson & JohnsonJNJ

$1.47B-56.6%

Merck & Co.MRK

$2.93B+150%

Gilead SciencesGILD

$2.43B+46.8%

Summit TherapeuticsSMMT

——

IncyteINCY

——

Other financials

Income statement

See full

Revenue$44.2M+168%

Gross profit$44.0M+167%

Operating income-$69.8M-8.3%

Net income-$632.8M-388%

EPS (diluted)-$0.62-313%

Balance sheet

See full

Cash & equivalents$205.2M+238%

Total debt$445.4M+32.2%

Total equity-$870.0M-47.1%

Total assets$646.6M+113%

Cash flow

See full

Operating cash flow-$75.4M+12.3%

CapEx$1.8M+58.4%

Valuation

See full

Market cap$7.71B+208%

Enterprise value$7.95B+187%

P/S54.7×-25.4×

Profitability

See full

Gross margin99.3%-0.5pp

Operating margin-185.4%-83.3pp

Net margin-606.2%-212pp

FCF margin-212%-95.8pp

Returns & leverage

See full

Return on equity-119.3%—

Debt / equity0.1×—

Current ratio6.7×+4.4×

Where this comes from

Calculated from ImmunityBio, Inc.’s reported figures.

−$75.4Mnet cash from operating−$1.8Mcapital expenditures=-$77.14M

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ImmunityBio, Inc.'s free cash flow?: ImmunityBio, Inc. (IBRX) reported free cash flow of -$77.14M in Q1 2026.
How has ImmunityBio, Inc.'s free cash flow changed year-over-year?: ImmunityBio, Inc.'s free cash flow increased by 11.4% year-over-year, from -$87.03M to -$77.14M.
What is the long-term trend for ImmunityBio, Inc.'s free cash flow?: Over 4 years (2021 to 2025), ImmunityBio, Inc.'s free cash flow has grown at a 0.1% compound annual growth rate (CAGR), from -$307.98M to -$308.78M.